Overview
The goal of this clinical trial is to evaluate the performance characteristics of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in differentiating pseudoprogression from tumour progression in patients with equivocal conventional imaging and determine the sensitivity and specificity of [18F]FET-PET in delineating disease. The main question[s] it aims to answer are:
- whether 18F-FET-PET will demonstrate high diagnostic accuracy to detect true tumour progression
- whether we can optimise the threshold cut-offs for TBRmax and other relevant parameters in discriminating pseudoprogression and disease progression Participants will undergo a limited 18F-FET PET/CT of the brain in SGH.
Eligibility
Inclusion Criteria:
- Men or Women, aged 21 years or older at time of screening
- Histologically confirmed diagnosis of malignant glioma (defined as WHO grade III or IV) with previous RT to tumour
- With enlarging contrast-enhancing and/or T2W/FLAIR-hyperintense lesion(s) on MRI within the previous RT field
- Gliomas with Isocitrate dehydrogenase (IDH) wild-type status, as defined on immunohistochemistry
- Subject must consent to undergo all study procedures
Exclusion Criteria:
- Low-grade gliomas (histology grade 1 or 2 by WHO classification)16,17
- Previous bevacizumab or other vascular endothelial growth factor (VEGF) targeting agents or anti-angiogenic treatments.
- Proven cerebral metastases
- IDH-mutated gliomas
- Pregnancy/ breast-feeding